Search results
Results from the WOW.Com Content Network
The original patent, U.S. patent 4,927,855, was granted to Laboratoire L. Lafon in 1990, covering the chemical compound of modafinil. This patent expired in 2010. [ 223 ] In 1994, Cephalon filed a patent for modafinil in the form of particles of a defined size, represented by U.S. patent 5,618,845 , which expired in 2015.
Provigil was initially approved to treat excessive daytime sleepiness resulting from narcolepsy, and later approved the drug for further label indications. Cephalon allegedly promoted Provigil for a five-year period as a non-stimulant drug for the treatment of sleepiness, tiredness, decreased activity, lack of energy, and fatigue.
Chemical structure of modafinil.. This page lists chemical compounds similar to modafinil, known as modafinil analogues and derivatives.These are structural analogues and derivatives of modafinil, a drug that affects dopamine levels in the brain in an unusual way (atypical dopamine reuptake inhibitor or DRI).
It spent $98,000 on 4,180 unit doses of Provigil, a brand name stimulant, 55 times more than the $1,800 the generic equivalent would have cost, the report found. Both drugs were disbursed without ...
A new Supreme Court ruling presents pharmaceutical companies with a tough choice -- stop paying generic-drug producers to withhold generic options from the market, or risk getting sued by ...
The clinic also spent nearly $100,000 during that period on Provigil, a stimulant that is “55 times more expensive than the generic equivalent,” the report said.
A Cephalon-founded study in which patients were administered modafinil, methylphenidate, and a placebo found that modafinil produces "psychoactive and euphoric effects and feelings consistent with [methylphenidate]." [12] Like modafinil, armodafinil is an inhibitor and/or inducer of certain cytochrome P450 enzymes.
Actiq/Gabitril/Provigil: Cephalon [19] $425,000,000 $375 million civil ($425 million with criminal component) Off-label promotion [20] False Claims Act/FDCA 2004 19 15 Claritin: Schering-Plough [21] $345,000,000 $290 million civil ($345 million with criminal component) Medicare fraud/kickbacks False Claims Act/ Anti-Kickback Statute 2017 20 16